Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Chief of Staff Burke

Executive Summary

Former HHS Chief of Staff Thomas Burke declines offer of staff director for Bipartisan Commission on Comprehensive Health Care and Long-Term Care, established under the Catastrophic Care Act. He plans to move to the private sector. The commission held its first organizational meeting Feb. 8 and elected Rep. Pepper (D-Fla.) chairman and Sens. Baucus (D-Mont.) and Durenburger (R-Minn.) vice chairmen. The commission meets again on Feb. 28 to set up a timetable for producing reports on long-term and comprehensive health care.

You may also be interested in...



Goop Exits NAD Review With Menopause Support Claim Affirmed For Madame Ovary Supplement

Gwyneth Paltrow’s Goop, Inc. demonstrated to the National Advertising Division’s satisfaction that Madame Ovary is “a daily regimen formulated to support thyroid health and smoothing the menopausal transition by providing nutritional support for women who may experience mild hot flashes, mood shifts, and stress-related fatigue.” Other ingredient-specific claims came up short.

New York State To Conduct Its Own Review Of COVID-19 Vaccines In Another Blow To FDA’s Reputation

Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.

Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity

Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel